Phathom Pharmaceuticals Inc (NASDAQ: PHAT) is 10.51% higher on its value in year-to-date trading and has touched a low of $6.07 and a high of $17.02 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PHAT stock was last observed hovering at around $10.10 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $10.09, the stock is 4.56% and 3.03% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.11 million and changing -0.10% at the moment leaves the stock 1.18% off its SMA200. PHAT registered -15.85% loss for a year compared to 6-month gain of 24.26%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -14.49% loss in the last 1 month and extending the period to 3 months gives it a 44.66%, and is 3.38% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.38% over the week and 7.32% over the month.
Phathom Pharmaceuticals Inc (PHAT) has around 452 employees, a market worth around $590.47M and $0.68M in sales. Profit margin for the company is -29558.80%. Distance from 52-week low is 66.36% and -40.71% from its 52-week high. The company has generated returns on investments over the last 12 months (-55.18%).
The EPS is expected to shrink by -25.55% this year
The shares outstanding are 57.97M, and float is at 28.15M with Short Float at 42.74%.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
The most recent transaction is an insider sale by Henderson Molly, the company’s CFO and CBO. SEC filings show that Henderson Molly sold 3,435 shares of the company’s common stock on Apr 08 ’24 at a price of $11.10 per share for a total of $38128.0. Following the sale, the insider now owns 95263.0 shares.
Phathom Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 22 ’24 that Curran Terrie (President and Chief Executive) sold a total of 16,851 shares of the company’s common stock. The trade occurred on Mar 22 ’24 and was made at $9.11 per share for $0.15 million. Following the transaction, the insider now directly holds 0.41 million shares of the PHAT stock.
Still, SEC filings show that on Jan 24 ’24, TAKEDA PHARMACEUTICAL CO LTD (10% Owner) disposed off 3,703,703 shares at an average price of $8.10 for $30.0 million. The insider now directly holds 3,755,583 shares of Phathom Pharmaceuticals Inc (PHAT).
